Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Clavis to develop companion diagnostic for AML

This article was originally published in Clinica

Executive Summary

Norwegian firm Clavis Pharma is to develop a test to detect and quantify human equilibrative nucleoside transporter 1 (hENT1) in acute myeloid leukaemia (AML) patients. The standard drug treatment for AML is cytarabine, but the entry of cytarabine into tumour cells depends on the expression of membrane transporter proteins, particularly hENT1. Clavis Pharma (Oslo, Norway) is developing a derivative of cytarabine called elacytarabine which can be taken up by cells regardless of hENT1 expression level. Thus, patients with low expression of the biomarker may be better treated with Clavis's drug rather than the standard therapy. Development of a flow cytometry test for hENT1 will be funded by a NOK14m ($2.5m) grant Clavis has received from The Research Council of Norway. The grant will cover up to 35% of the total project cost, Clavis says.

You may also be interested in...



Five minutes with… Noam Emanuel of PolyPid

Dr Noam Emanuel is the founder and chief technology officer of Ness Ziona, Israel-based drug delivery firm PolyPid. The 15-strong firm, established in 2008, has developed an encapsulation technology which allows the precise targeting of drug release.

Mesoblast's blood cancers stem cell therapy moves closer to market

Mesoblast has received the all-clear from the US FDA to start a Phase III clinical trial for bone marrow regeneration in patients with blood cancers. The study will be conducted together with Mesoblast's strategic alliance partner, Cephalon, which will fund the trial.

Mesoblast stem cell therapy advances into Phase II for spinal degeneration

Mesoblast has received the green light from the US FDA to begin a Phase II trial of its proprietary adult mesenchymal precursor cell (MPC) product for the treatment of degenerative disc disease, a major cause of chronic low back pain.

Topics

UsernamePublicRestriction

Register

MT097355

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel